Physicians' Academy for Cardiovascular Education

Inflammation: The next therapeutic frontier in targeting cardiovascular risk

This series consists of an introduction, three presentations and a discussion in which four experts in this field will bring you up to date on the role of inflammation in atherosclerosis and how to translate findings from science and clinical trials into practice.

E-learning Inflammation: The next therapeutic frontier in targeting cardiovascular risk

Accredited e-Learning

Online-CME - This course consists of 4 parts.
This course consists of 4 parts.

"There are 3 patients with residual inflammatory risk for every 1 patients with residual cholesterol risk," says prof. Ridker. Learn how perspectives on inflammation in atherosclerosis have changed from 1970s up until now and how (novel) anti-inflammatory therapies may reduce CVD risk.

Slides: IL-6 as therapeutic target in inflammation and CVD

Slides (presentation) - May 4, 2022 - Online series on inflammation in atherosclerosis
These slides from a presentation by Paul Ridker, MD, are part of an educational series entitled

Slides as educational service to PACE members.

The journey from hypothesis to reality on inflammation in CVD

10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD
On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality.

On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality. "Ultimately, the inflammation hypothesis is going to yield great dividends for our patients", concluded prof. Libby.

IL-6 as therapeutic target in inflammation and CVD

10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD

"There are 3 patients with residual inflammatory risk for every 1 patients with residual cholesterol risk," says prof. Ridker. What are current and future therapies to lower inflammation in these patients with residual inflammatory risk?

Inflammation and anti-inflammatory therapy in CVD

10' education - Apr. 11, 2022 - Prof. Thomas Lüscher, MD
What is the role of inflammation in the occlusion of coronary arteries? Prof. Lüscher presents findings from studies on this topic and discusses outcomes of trials with anti-inflammatory therapies.

What is the role of inflammation in the occlusion of coronary arteries? Prof. Lüscher presents findings from studies on this topic and discusses outcomes of trials with anti-inflammatory therapies.

Slides: Inflammation and anti-inflammatory therapy in CVD

Slides (presentation) - Mar. 30, 2022 - Online series on inflammation in atherosclerosis
These slides from a presentation by Thomas Lüscher, MD, are part of an educational series entitled

Slides as educational service to PACE members.

Slides: 3 Challenges when targeting inflammation in residual CV risk

Slides (presentation) - Mar. 29, 2022 - Online series on inflammation in atherosclerosis
These slides from a presentation by Filippo Crea, MD, are part of an educational series entitled

Slides as educational service to PACE members.

Slides: Immunity and inflammation in atherosclerosis - no longer just a theory

Slides (presentation) - Mar. 29, 2022 - Online series on inflammation in atherosclerosis
These slides from a presentation by Peter Libby, MD, are part of an educational series entitled

Slides as educational service to PACE members.

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD
Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Immunity and inflammation in atherosclerosis - no longer just a theory

10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD
Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

Inflammation: The next therapeutic frontier in targeting cardiovascular risk